

**Ref: MHL/Sec&Legal/2025-26/79**

**January 05, 2026**

To,  
**BSE Limited**  
Scrip Code: 542650

**National Stock Exchange of India Ltd.**  
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended December 31, 2025.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended December 31, 2025. A detailed information update will follow once the Board of Directors approve the financial results for Q3FY26.

The company delivered a **strong 26% year-on-year consolidated revenue growth**, driven by sustained momentum in preventive and wellness health check-ups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels. Supported by an expanded Core Diagnostics test menu for high-end specialty testing and continuous in-house innovation, the company has successfully scaled its specialty business across its pan-India network.

### **Key highlights of Q3FY26 (MHL Group):**

1. Revenue growth is approx. **26% on a Y-o-Y** basis including revenues from Core Diagnostics, Scientific Pathology (Scientific), Agra, Dr. Ahuja's Pathology & Imaging Center (DAPIC), Dehradun and Dr. RS Patil's Ambika Pathology Laboratory, Kolhapur (Ambika Pathology).
2. The integration of all acquisitions are progressing well, with synergies delivering operational efficiencies and strengthening operating leverage, supported by continued growth in revenues and profitability. Core Diagnostics margins are trending in line with our estimates and remained similar to Q2 levels. DAPIC (Dehradun), Scientific (Agra), and Ambika (Kolhapur) continue to outperform the Company's average margins.
3. The TruHealth Wellness and Specialty segments recorded Y-o-Y growth of ~35% and ~33%, respectively, in Q3FY26.
4. B2C revenues registered a Y-o-Y growth of around 18% on a Y-o-Y basis and B2B revenue growth stood at ~37% on the back of addition of wallet share among customers especially for specialty segment & on account of higher contribution of B2B business in Core Diagnostics.

### **Key highlights of Q3FY26 (Standalone):**

1. Revenues grew by approx. **15% Y-o-Y**, largely on account of increased patient and test volumes and a favorable shift in product mix and realizations.
2. Truhealth wellness segment and Specialty segment grew by ~23% and ~16% respectively on a **Y-o-Y** basis.



3. B2C revenues registered a growth of **14%** and B2B segment registered a revenue growth of **16%** on a **Y-o-Y** basis.
4. EBITDA margins for the quarter recorded year-on-year expansion, despite Q3 being a seasonally weaker period for the diagnostic industry. The margin improvement highlights the resilience of company's operations and the strength of operating leverage embedded in its business model.

The quarterly business update is on a consolidated basis. The financial results of Q3FY26 are subject to review by Auditors.

Thanking you,  
Yours faithfully,

**For Metropolis Healthcare Limited**

Kamlesh C Kulkarni  
Head – Legal & Secretarial

